Careem honors outstanding captains in Riyadh

Several rewards were handed out along with the grand prize, a brand new car, at the event. (Photo/supplied)
Updated 12 December 2018

Careem honors outstanding captains in Riyadh

Careem held the first edition of its Captain’s Excellence Award Ceremony in Riyadh on Saturday. The event, which will be held annually, was the first-of-its-kind in the region and welcomed over 300 top-performing “captains” (Careem drivers) across the Kingdom. 

The captains were awarded based on different criteria such as: Captains with the highest number of trips, highest (customer-given) ratings and longest serving captains. Rewards were also handed out to captain ambassadors, i.e. those with the highest number of referrals and captains that were given a special shoutout on social media by customers for their dedication to their service. Several rewards were handed out along with the grand prize, a brand new car. 

Abdulla Elyas, chief people officer and co-founder of Careem, opened the event with an ode to the captains in attendance, thanking them for their service and commitment in driving impact through meaningful initiatives across the Kingdom. Some of these initiatives included the vaccination campaign in collaboration with the Ministry of Health, which helped more than 100,000 men, women and children across 17 cities get vaccinated in their own homes. Careem also collaborated with Bupa Arabia during Ramadan this year to donate clothes from customers to people in need, where over 180,000 donations were collected. 

Elyas also announced Careem’s partnership with Alwaleed Philanthropies (AP) in delivering the first installment of cars for the empowerment of people with special needs. The foundation, chaired by Prince Alwaleed bin Talal, will provide a number of cars over the course of seven years to men and women of the Society for Physically Disabled Adults (Harakia) after being trained.

“Our captains are the lifeblood of our business and we wanted to celebrate these men and women for helping us achieve our mission of simplifying and improving the lives of people in the Kingdom,” Elyas said. 

“We are proud to have 395,000 ‘captainahs’ (female drivers) and captains registered with us to date in Saudi Arabia, providing over 122 million rides. This ceremony is our small way to thank them for their service and reward them for the hard work they put in every day so that people have a safe way to get around. Without them, we wouldn’t be where we are today” 

Muaaed Al-Saeed, a representative from the Public Transport Authority (PTA), said: “We are excited to have you all; you have overcome each obstacle you were faced with in a short span of time and for that we are extremely proud.” 

He added: “On this occasion, I convey the regards of PTA President Dr. Rumaih Al-Rumaih. The participation of myself and Majed Al-Zahrani, PTA general manager, is proof of our support to all the captains.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.